Incyte Scraps Early Jakafi Successor on PK Failure, Deepening 2028 Patent Cliff Risk

Incyte Discontinues Early-Stage Cancer Drug INCB160058

Incyte has announced the discontinuation of INCB160058, an early-stage experimental JAK2V617F inhibitor, to reallocate resources towards more promising "next-generation" therapies. The decision was influenced by the asset's "poor" pharmacokinetic profile and underwhelming data. INCB160058 was undergoing a Phase 1 study for myeloproliferative neoplasms. This strategic shift aligns with investor focus on Incyte's late-stage cancer programs, INCA033989 and INCB161734, as the company prepares for the 2028 patent expiration of its leading product, Jakafi. Incyte reported strong Q2 net sales of nearly $1.49 billion, a 40% increase year-on-year, with Jakafi contributing $816 million and Opzelura surging to almost $450 million.

• Incyte discontinued INCB160058, an orally available JAK2V617F inhibitor, citing a "poor" pharmacokinetic profile and underwhelming efficacy and safety data. Global head of R&D, Pablo Cagnoni, confirmed the decision was made to prioritize the company's next-generation pipeline, emphasizing that continued development of the asset was not strategically sound given other programs.
• The discontinuation of INCB160058 enables Incyte to intensify its focus on key late-stage pipeline assets, including the antibody INCA033989 for myelofibrosis and essential thrombocytopenia, and the KRAS G12D blocker INCB161734 for pancreatic cancer. This prioritization is crucial for Incyte's long-term growth strategy as it seeks to mitigate the impact of the 2028 patent cliff for its top-selling drug, Jakafi.
• Incyte demonstrated robust financial performance in the second quarter, achieving nearly $1.49 billion in net sales, a 40% increase from the previous year. While Jakafi remained a significant contributor with $816 million in sales, growth was largely driven by Opzelura, which saw a 173% sales surge to almost $450 million and recently secured European approval for moderate atopic dermatitis. The company also highlighted contributions from Monjuvi and Niktimvo, and a recent $2 billion acquisition of Vega Therapeutics for a late-stage bleeding disorder program.

The Genetic Drivers of Myeloproliferative Neoplasms

Myeloproliferative neoplasms (MPNs) are primarily driven by somatic, gain-of-function mutations that constitutively activate the JAK-STAT signaling pathway. The three cardinal driver mutations occur in JAK2, CALR, and MPL. The most prevalent of these, the JAK2 mutation, was identified in 2005 and is found in 90–98% of patients with polycythemia vera and approximately 50% of those with essential thrombocythemia or primary myelofibrosis. This mutation leads to constitutive activation of the JAK2 kinase, which phosphorylates STAT proteins. The phosphorylated STATs then dimerize, translocate to the nucleus, and initiate the transcription of target genes that mediate cell growth, differentiation, and apoptosis, thereby driving the proliferation of the neoplastic clone. This central mechanism is further amplified by a JAK-activated feed-forward loop involving the cytokine-like ligand Upd3 and its receptor, Domeless.

Beyond the canonical drivers, a diverse array of additional genetic and molecular alterations contributes to MPN pathogenesis. Secondary somatic mutations are frequently observed in genes such as TET2, LNK, IDH1/2, and ASXL1. Novel somatic mutations in receptor tyrosine kinases, such as a recently identified activating mutation in ERBB1/EGFR, have also been reported, alongside elevated EGFR levels in MPN samples. Other signaling pathways also play a role; for instance, a pro-tumorigenic crosstalk exists between the p38 MAPK pathway and JAK signaling, with p38 MAPK inducing the expression of the Upd3 ligand. Furthermore, the downregulation of Growth Arrest and DNA Damage Inducible Gamma (GADD45g), a tumor suppressor, is a key event. GADD45g insufficiency, partly caused by the JAK2V617F mutation, enhances the self-renewal of hematopoietic stem cells and promotes MPN-like phenotypes through the activation of RAC2, PAK1, and PI3K-AKT signaling.

The cellular microenvironment and specific transcription factors are also critical in MPN progression. Bone marrow-derived mesenchymal stromal cells (BM-MSCs) from MPN patients contribute to fibrosis by differentiating into αSMA-positive myofibroblasts and producing a dysregulated extracellular matrix. These fibrotic changes can be induced in healthy BM-MSCs simply by co-culture with MPN mononuclear cells. In the vasculature, JAK2-expressing endothelial cells promote thrombosis by adopting a pro-adhesive phenotype characterized by increased P-selectin exposure. Moreover, sustained overexpression of the transcription factor NF-E2 can induce a myeloproliferative state with leukocytosis and thrombocytosis. This creates a state of chronic inflammation, driven by activated leukocytes and platelets, which may itself trigger and sustain clonal myeloproliferation.

Exploring Novel Targets in Myeloproliferative Neoplasms

The therapeutic landscape for myeloproliferative neoplasms (MPNs) is rapidly evolving beyond conventional JAK inhibition. Current research is focused on developing novel agents that target more specific molecular pathways, the tumor microenvironment, and unique neoantigens to achieve deeper, more durable responses and overcome existing treatment limitations.

• Next-Generation JAK Inhibitors: New strategies are being developed to enhance the specificity of JAK2 inhibition. These include Type II inhibitors that bind the kinase domain in its inactive state and agents targeting the pseudokinase domain, both with the potential for greater selectivity for the JAK2 V617F mutant. The goal is to eradicate the malignant clone while sparing wild-type JAK2, which is critical for normal hematopoiesis and immune function.

• ULK1 Kinase Pathway: ULK1 kinase has emerged as a key therapeutic target, playing a protumorigenic role downstream of hyperactive JAK2 signaling. In preclinical MPN models, genetic or pharmacological targeting of ULK1, which is essential for the transcription of hematopoietic stem cell differentiation genes, has been shown to substantially delay disease development, reduce spleen size, and decrease erythroid progenitor counts.

• Mutant Calreticulin (CALR): The neomorphic C-terminus generated by CALR mutations represents a highly specific and compelling target for immunotherapy. Because this neoepitope is absent from the normal proteome, it enables the development of targeted approaches such as vaccines, antibody-based strategies, and T-cell therapies that have demonstrated the ability to elicit T-cell responses against the mutant clone.

• Tumor Microenvironment and Immune Modulation: Several approaches target the complex interplay between MPN cells and their microenvironment. These include immune checkpoint inhibitors (PD-1/PD-L1 blockade) to counteract T-cell exhaustion, anti-TGF-β agents to address bone marrow fibrosis and megakaryocyte expansion, and CXCR1/2 antagonists to modulate chemokine signaling.

• Novel Therapeutic Classes: Agents with distinct mechanisms are expanding treatment options. Momelotinib, a JAK1/2 and ACVR1/ALK2 inhibitor, is particularly effective for patients with significant anemia. Other non-JAK inhibitor therapies, such as erythropoiesis-stimulating agents and androgens, are also being utilized for managing cytopenic myelofibrosis.